Last reviewed · How we verify

NCT07412314

Proton Therapy for Recurrent Nasopharyngeal Carcinoma

Recruiting now NA Last updated 9 March 2026
What this trial tests

NA trial testing Proton therapy in Recurrent Nasopharyngeal Carcinoma in 52 participants. Currently enrolling.

Timeline
10 March 2025
Primary endpoint
10 March 2028
10 March 2028

Quick facts

Lead sponsorGuangzhou Concord Cancer Center
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment52
Start date10 March 2025
Primary completion10 March 2028
Estimated completion10 March 2028
Sites2 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangzhou Concord Cancer Center

Who can join

18 and older, any sex, with Recurrent Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Proton therapy

Trials testing the same drug.

Other recruiting trials for Recurrent Nasopharyngeal Carcinoma

Currently open trials in the same condition.

Other Guangzhou Concord Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07412314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing